在2型糖尿病患者中,甘油三指数与高尿素血症之间的关联
Xu Sun1,2,3, Xin Li1,2, Zhuyin Qian4
1Department of Pharmacy, Nanjing Luhe People's Hospital, Nanjing, China.
Frontiers in endocrinology
|November 3, 2025
概括
甘油三糖 (TyG) 指数与中国2型糖尿病 (T2DM) 患者的高尿血症 (HUA) 风险较高有关. 早期干预可以减少与HUA相关的并发症.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 心血管健康 心血管健康
背景情况:
- 胰岛素抵抗是2型糖尿病 (T2DM) 的关键因素.
- 甘油三糖指数 (TyG) 作为胰岛素耐药性的替代标记.
- 超尿血症 (HUA) 是一种与心血管风险增加相关的代谢障碍.
研究的目的:
- 调查TyG指数与中国T2DM患者高尿血症 (HUA) 风险之间的关联.
- 在这个人群中探索TyG指数对HUA的预测值.
主要方法:
- 一项涉及996名来自中国南京的T2DM患者的横截面研究.
- 参与者根据他们的TyG指数被分为四分之一.
- 用物流回归和限制立方线 (RCS) 分析来评估TyG-HUA关系.
主要成果:
- 与最低四分位数 (P=0.008) 相比,最高的TyG指数四分位数显示HUA风险增加了4.23倍.
- RCS分析表明,TyG指数与HUA风险之间存在非线性关联 (非线性P=0.044).
- 在显示下降趋势之前,HUA风险最初随着TyG水平的上升而增加.
结论:
- 提升的TyG指数是T2DM患者HUA风险的独立预测指标.
- 针对TyG指数的早期代谢干预可能有助于减少与HUA相关的心血管发病率和死亡率.
更多相关视频
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
71.3K
06:59Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
Published on: November 13, 2016
11.4K
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Diabetes: Symptoms, Diagnosis, and Complications
2.0K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones
571
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
571
Diabetes Mellitus: Overview and Type I Subtype
4.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K
Oral Hypoglycemic Agents: Sulfonylureas
752
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
752
Hypoglycemia and Glucagon
796
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
796
